36 results about "Pirarubicin" patented technology

Disclosed is a compound anticancer slow release agent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer effective ingredients include Aclarubicin, Idarubicin, Doxorubicin, Epirubicin, Valtaxin, Pirarubicin, Losaxantrone, Losoxantrone and / or anticancer antibiotic synergistic agents selected from phosphoinositide-3-kinase inhibitor, pyrimidine analogues and / or DNA restoration enzyme inhibitor, the slow release auxiliary materials are selected from polylactic acid copolymer EVAc, or sebacic acid copolymer, the viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C). The slow release microspheres can also be prepared into slow release implanting agent for lowering down the whole body toxicity reaction of the medicament when locally dispensing on the tumor, and for selectively increasing the tumor local medicinal concentration.

The invention relates to a temperature-controlled sustained-release injection containing an anti-cancer drug, which consists of the anti-cancer drug and an amphiphilic block copolymer hydrogel and has the temperature-sensitive gelatinization feature, the temperature-controlled sustained-release injection is flowable liquid in the environment that is lower than the body temperature and can be automatically converted to the water-insoluble gel that can not flow and be biodegradable for absorption in an endotherm, thus allowing the drug to have the local sustained release in a tumor and maintain the effective drug concentration for a plurality of weeks to a plurality of months; the temperature-controlled sustained-release injection can be injected in the tumor or the tumor periphery or be arranged in the postoperative tumor cavity, thus significantly reducing the systemic reaction of the drug, strengthening the treatment effects of chemotherapy, radiotherapy and other non-surgical therapies, and being used for the treatment of the tumors in different stages. The anti-cancer drug can be vincristine, vinorelbine, navelbine, vindesine, vinleurosine, vinrosidine, cephalotaxine, bleomycin, daunomycin, aclarubicin, epirubicin, idarubicin, pirarubicin, valrubicin, mitomycin C, actinomycin D, losoxantrone, mitoxantrone, mitozolomide, temozolomide and so on.

The present invention relates to polymeric antitumor agent which is formed in polymeric micelle complex by intermolecular bonding or mutual interaction between styrene maleic acid copolymer (SMA) and low molecule antitumor agent which is anthracyclins drug such as pirarubicin, doxorubicm, epirbicin, daunorbicin, acralbicin, or alkaloid antitumor agent such as cis-platinum, and taxol These polymeric antitumor agents may improve specificity to cancer cells so that it improves antitumor effect, while it may not be concentrated at normal organ or tissue, so that adverse effect may be diminished. These polymeric antitumor agents may be prepared by dissolving SMA and low molecule antitumor agent in aqueous solution, then in the presence of aqueous soluble carbodiimide, amino acids, or polyamine, adjusting pH to form micelle complex and recovering polymer fraction.

The invention discloses a composition for treating the bladder cancer and application of hydrogen physiological saline. The composition includes hydrogen physiological saline and chemotherapeutic drugs, wherein the chemotherapeutic drugs are one or more of cisplatin, adriamycin, hydroxycamptothecin, pirarubicin, epirubicin and gemcitabine. Through the hydrogen physiological saline, the growth of in-vitro bladder cancer cells can be inhibited significantly, apoptosis of tumor cells is promoted; and in addition, exogenous hydrogen taken through respiration or drinking or injection has good histocompatibility, safety, and few side effects, even if the taken exogenous hydrogen is excessive, the taken exogenous hydrogen can be discharged through respiration without residues.

This invention relates to methods and compositions for treatment of inv(16) leukemia and particularly to treatment of acute myeloid leukemia. Disclosed is a method of treating inv(16) leukemia comprising the step of administering to a subject in need thereof a therapeutically effective combination of a) a compound of the formula (1) and b) a chemotherapeutic agent selected from the group consisting of pirarubicin, aclarubicin, mitoxantrone, doxorubicin, daunorubicin, idarubicin, epirubicin, cytarabine, pharmaceutically acceptable salts and mixtures thereof. The therapeutically effective combination synergistically inhibits proliferation of inv(16) leukemia cells. This invention also relates to pharmaceutical compositions comprising a therapeutically effective combination of the compound of formula (1) and the chemotherapeutic agent and a pharmaceutically acceptable excipient.

Disclosed is an anticancer slow release agent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow releaseauxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer antibiotics are selected from Idarubicin, Valtaxin, Pirarubicin and Mitoxantrone, The anti-metabolite drugs are selected from Pemetrexed, Carmustine, Tegafur, Zalcitabine, Emtritabine, Galocitabine, Ibacitabine, Ancitabine, Decitabine, Flurocitabine, Enocitabine, Imidazoletabine, Capecittabine, Gemcitabine, Fludrarbine, Raltitrexed, Dexrazoxane, Cladribine, Nolatrexed and folic acid, The slow release auxiliary materials are selected from EVAc, Polifeprosan, sebacylic acid copolymer, lactic acid, the viscosity of the suspension adjuvant is 100-3000cp (at 25-30 deg C), and is selected from sodium carboxymethylcellulose. The slow release microspheres can also be prepared into slow release implanting agent for injection or placement in or around tumor.

The present invention relates to the technical field of slow-release medicine preparation, specifically a pirarubicin drug-loaded gelatin submicroemulsion material and its preparation method and application. The present invention firstly prepares the gelatin water phase material A, and then mixes it with the oil phase Material B was blended to prepare W / O type blank gelatin material C, and pirarubicin was coated by using W / O type blank gelatin material C; pirarubicin was combined with W / O type blank gelatin material The compatibility of C is poor, so before coating, pirarubicin is dissolved in a glucose solution with a volume fraction of 5%, and under the action of glucose solution, pirarubicin is coated with W / O type Blank gelatin material C, and then obtain the structurally stable pirarubicin gelatin drug-loaded submicron emulsion material. The invention not only prepares a pirarubicin gelatin drug-loaded submicron emulsion material, but also the pirarubicin gelatin drug-loaded submicron emulsion material can be applied to the preparation of slow-release antitumor drugs.

Disclosed is a compound anticancer slow release agent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slowrelease auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer effective ingredients include Aclarubicin, Idarubicin, Doxorubicin, Epirubicin, Valtaxin, Pirarubicin, Losaxantrone, Losoxantrone and / or anticancer antibiotic synergistic agents selected from phosphoinositide-3-kinase inhibitor, pyrimidine analogues and / or DNA restoration enzymeinhibitor, the slow release auxiliary materials are selected from polylactic acid copolymer EVAc, or sebacic acid copolymer, the viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C). The slow release microspheres can also be prepared into slow release implanting agent for lowering down the whole body toxicity reaction of the medicament when locally dispensing on the tumor, and for selectively increasing the tumor local medicinal concentration.

The invention relates to a preparation method for a Sappan Wood extract, in particular to a preparation process for Sappan Wood extract perfusate and application thereof in treating bladder cancer, which solves the problem of the application of the Sappan Wood extract in treating bladder cancer tumors. The preparation process comprises the following steps: taking and smashing Sappan Wood, carrying out water extracting for three times, combining the extracting solutions obtained by three-time water extracting, and carrying out decompression concentrating; standing overnight, and removing sediments; adding petroleum ether, extracting, and retaining aqueous phase; adding ethyl acetate, extracting, and removing the aqueous phase; carrying out decompression volatilizing to remove all the ethylacetate; weighing dry substances, adding purified water to enable the dry substance content to be 2%, heating for dissolving, standing overnight at room temperature, and filtering out sediments; and freeze-drying, and carrying out split charging. The experiment research result shows that the extract has obvious killing effect on bladder neoplasm cells; and compared with mitomycin, epirubicin, Pirarubicin and other anticancer drugs, which are clinically and frequently used, the Sappan Wood extract perfusate has the advantages of high anticancer activity, less toxicity, safety, effectiveness and the like.

An instant freeze-dried powder injection of pirarubicin is prepared from pirarubicin, excipient and cosolvent through proportionally dissolving them in the water for injection, aseptic filtering, loading in containers, and freeze-drying.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a magnetic pirarubicin nano-drug composite. The magnetic pirarubicin nano-drug composite comprises pirarubicin, an Fe3O4 nanoparticle and 3-aminopropyl triethoxysilane, wherein the particle diameter of the Fe3O4 nanoparticle is 10-100 nanometers. The magnetic pirarubicin nano-drug composite disclosed by the invention has good stability and dispersity and property of being positioned to a tumour part in a targeted way through an external magnetic field and reduces the toxic side effect on a normal structure by restricting the dual inhibiting effect of THP and Fe3O4 on a cell on a specific tumour part.

Relating to the field of pharmacy, the invention in particular provides an anti-tumor pharmaceutical composition containing total flavonoids of apocynum venetum leaves. The pharmaceutical composition is composed of total flavonoids of apocynum venetum leaves and an anthracycline drug, wherein the anthracycline drug is pirarubicin or epirubicin. The pharmaceutical composition provided by the invention has better antitumor effect than anthracycline drugs, also effectively alleviates or avoids the cardiac toxicity of patients, and reduces the toxic and side effects.

The invention relates to maleic acid ammonia pirarubicin salt and its preparation method, and its application in antineoplastics and pharmaceutical preparation. The preparation method includes reaction in solvent, freeze drying, or crystallizing.